South Korea has reduced National Health Insurance prices for 80 medicines by an average of 4.6% under the 2026 Type C volume-price linkage scheme, including Yuhan Corporation's Rosuvamibe, Celltrion's Remsima and Remsima SC, and JW Pharmaceutical's Livarojet. The National Health Insurance Service completed negotiations covering 81 products, with one fertility treatment retaining its price under a one-time rebate contract. The reductions took effect on the 1st of this month and are expected to save about 33.9 billion won ($24.5 million), broadly matching last year's savings despite fewer products being covered. Hypertension and dyslipidemia medicines made up 43.2% of the products receiving cuts, reflecting increased use of long-term treatments as South Korea's population ages and chronic disease becomes more prevalent.